A randomised, participant- and assessor-blinded, sham-controlled trial investigating acupuncture for disorders of gut-brain interaction in children (P-GAP)
Abstract
Background: Disorders of gut-brain interaction (DGBIs) affect approximately 25% of children worldwide and account for a substantial proportion of paediatric gastroenterology consultations. These conditions are associated with significant morbidity, including chronic pain, school absenteeism, anxiety and reduced quality of life. Current treatment options offer limited efficacy, particularly in paediatric populations. Acupuncture, a widely used complementary therapy, has shown promise in adult DGBIs; however, high-quality evidence in children is lacking. The Paediatric Gut-Brain Acupuncture Protocol aims to evaluate the efficacy and safety of acupuncture in paediatric patients with DGBIs.
Methods and analysis: This randomised, participant-blinded and assessor-blinded sham-controlled trial will enrol 96 children aged 8-17 years with a diagnosis of DGBIs defined by Rome IV criteria. Participants will be randomised 1:1 to receive either standardised acupuncture or sham acupuncture one time per week for 8 weeks. The primary outcome is adequate pain relief, defined as a≥30% reduction in mean abdominal pain severity on the 11-point Numerical Rating Scale from baseline to follow-up at weeks 12-14. Secondary outcomes include change in mean abdominal pain severity, pain frequency, Rome IV diagnostic status, health-related quality of life, psychological well-being and safety. Outcomes will be assessed at baseline, weeks 4 and 8 during treatment and at post-treatment follow-up at weeks…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 96 participants or records.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.